Eva van Grinsven

18 Chapter 1 16. Khuntia D, Brown P, Li J, et al. Whole-brain radiotherapy in the management of brain metastasis. Journal of Clinical Oncology 2006; 24: 1295–1304. 17. Mehta MP. The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients. Neuro Oncol 2015; 17: 919–923. 18. Wilke L, Andratschke N, Blanck O, et al. ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams. Strahlentherapie und Onkologie 2019; 195: 193–198. 19. Grosshans DR, Meyers CA, Allen PK, et al. Neurocognitive function in patients with small cell lung cancer: effect of prophylactic cranial irradiation. Cancer 2008; 112: 589–595. 20. Vardy J, Dhillon HM, Pond GR, et al. Cognitive function and fatigue after diagnosis of colorectal cancer. Annals of Oncology 2014; 25: 2404–2412. 21. Mitchell T, Turton P. ‘Chemobrain’: Concentration and memory effects in people receiving chemotherapy - a descriptive phenomenological study. Eur J Cancer Care (Engl) 2011; 20: 539–548. 22. Makale MT, McDonald CR, Hattangadi-Gluth JA, et al. Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. Nat Rev Neurol 2017; 13: 52–64. 23. Greene-Schloesser D, Robbins ME, Peiffer AM, et al. Radiation-induced brain injury: A review. Front Oncol 2012; 2 JUL: 1–18. 24. Duffau H. Why brain radiation therapy should take account of the individual structural and functional connectivity: Toward an irradiation “à la carte”. Crit Rev Oncol Hematol; 154. Epub ahead of print 2020. DOI: 10.1016/j. critrevonc.2020.103073. 25. Mitchell AJ, Kemp S, Benito-León J, et al. The influence of cognitive impairment on health-related quality of life in neurological disease. Acta Neuropsychiatr 2010; 22: 2–13. 26. Frost MH, Sloan JA. Quality of life measurements: A soft outcome - Or is it? American Journal of Managed Care 2002; 8: 574–579. 27. Hodgson KD, Hutchinson AD, Wilson CJ, et al. A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 2013; 39: 297–304. 28. Joly F, Castel H, Tron L, et al. Potential effect of immunotherapy agents on cognitive function in cancer patients. J Natl Cancer Inst 2020; 112: 123–127. 29. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 2012; 12: 267–275. 30. Schagen SB, Tsvetkov AS, Compter A, et al. Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach? Nat Rev Neurol 2022; 18: 173–185. 31. Karnath HO, Sperber C, Rorden C. Mapping human brain lesions and their functional consequences. Neuroimage 2018; 165: 180–189. 32. Vaartjes I, Reitsma JB, De Bruin A, et al. Nationwide incidence of first stroke and TIA in the Netherlands. Eur J Neurol 2008; 15: 1315–1323. 33. Karnath HO, Berger MF, Küker W, et al. The anatomy of spatial neglect based on voxelwise statistical analysis: A study of 140 patients. Cerebral Cortex 2004; 14: 1164–1172. 34. Akeret K, Staartjes VE, Vasella F, et al. Distinct topographic-anatomical patterns in primary and secondary brain tumors and their therapeutic potential. J Neurooncol 2020; 149: 73–85.

RkJQdWJsaXNoZXIy MTk4NDMw